Roger Cady, MD: The Impact of Eptinezumab on Medication Overuse Headache

As headache specialists know all too well, medication overuse headache (MOH) can be extraordinarily challenging to treat. In recent years, a number of new therapies, such as those targeting calcitonin gene-related peptide (CGRP), have had their ability to reduce its occurrence and the need for rescue medication assessed in studies.

At the American Headache Society (AHS) Virtual Annual Scientific Meeting on June 13, 2020, data presented on eptinezumab (Vyepti; Lundbeck) suggested that treatment with the agent offered consistent improvements across patient-reported outcomes after treatment compared with placebo in those with MOH and chronic migraine. Eptinezumab additionally displayed a rapid effect on those who were treated with it in the PROMISE-1 (NCT02559895) and PROMISE-2 (NCT02974153) double-blind studies, with ≥50% reductions in migraine observed just a day post-dose.

In this interview with NeurologyLive, Cady offered his insight into how this agent may be able to help with MOH, and provided the takeaways for the clinical community.